The Masonic Cancer Center (MCC) is an NCI-designated Comprehensive Cancer Center dedicated to cancer research, education, and patient care for the citizens of Minnesota and the surrounding region. Since the time of the first award in 1997, there has been growth of the membership and research base. In our original application, there were 89 members, this has increased to 229 members from 53 departments and 13 colleges and schools of the University of Minnesota. Since our last renewal, there has been growth in NCI-funded research from $35.5M to $41.1M, an increase of almost 16%. Total cancer related research funding has increased by 6% to $94.0 in 2017 from $88.7M in 2013. The MCC is organized into 6 Programs that focus on specific scientific themes: Screening, Prevention, Etiology and Cancer Survivorship; Carcinogenesis and Chemoprevention; Genetic Mechanisms; Cell Mechanisms: Immunology; and Transplant Biology and Therapy. These Programs are supported by 10 Shared Resources. The past funding period has seen increased emphasis on developing our translational pipeline. Several resources and organizational structures have been put into place to support this effort and to better connect the basic programmatic research with the clinic. These resources include a Cancer Research Translational Initiative to increase the number of investigator-initiated translational trials at MCC and the formation of Translational Working Groups that bring together researchers, clinicians, and others in the oncology community to solve problems in organ-site-specific cancers. We have also established several mechanisms to increase the involvement of the community, and particularly the underserved populations in our catchment area, in clinical research. The MCC is a successful matrix organization in a large public research university that engages its faculty to focus on the problem of cancer. Our last period of support has been characterized by growth, stability in our leadership, enhanced engagement of our community, and creation of several new cancer-focused initiatives.

Public Health Relevance

Overall Narrative The Masonic Cancer Center is an NCI-Designated Cancer Center that creates a collaborative research environment focused on the causes, prevention, detection, and treatment of cancer; applying that knowledge to improve quality of life for patients and survivors; and sharing its discoveries with other scientists, students, professionals, and the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA077598-22S3
Application #
10243556
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1998-06-01
Project End
2024-01-31
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Regan Anderson, Tarah M; Ma, Shihong; Perez Kerkvliet, Carlos et al. (2018) Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis. Mol Cancer Res 16:1761-1772
Santiago, Victor; Lazaryan, Aleksandr; McClune, Brian et al. (2018) Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma 59:958-966
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Boatman, Jeffrey A; Vock, David M; Koopmeiners, Joseph S et al. (2018) Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. Biostatistics 19:103-118
Guo, Jingshu; Villalta, Peter W; Weight, Christopher J et al. (2018) Targeted and Untargeted Detection of DNA Adducts of Aromatic Amine Carcinogens in Human Bladder by Ultra-Performance Liquid Chromatography-High-Resolution Mass Spectrometry. Chem Res Toxicol :
Teitelbaum, A M; Murphy, S E; Akk, G et al. (2018) Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. Pharmacogenomics J 18:136-143
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. Br J Haematol 182:887-894
Bellamri, Medjda; Xiao, Shun; Murugan, Paari et al. (2018) Metabolic Activation of the Cooked Meat Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine in Human Prostate. Toxicol Sci 163:543-556
Murphy, Sharon E; von Weymarn, Linda B; Parenteau, Marc et al. (2018) Influence of UGT2B10 Genotype on Urinary Excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N-glucuronide by African American Smokers. Chem Res Toxicol 31:168-175
Hegerova, Livia; Bachan, Adam; Cao, Qing et al. (2018) Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 24:e20-e25

Showing the most recent 10 out of 1013 publications